News Column

Harwood Feffer LLP Announces Investigation of Intercept Pharmaceuticals, Inc.

January 27, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT), concerning whether the board has breached its fiduciary duties to shareholders (see also Harwood Feffer Llp ). On January 10, 2014 , the Company announced positive results in a clinical trial of obeticholic acid ("OCA"). On this news, Intercept stock increased over 500% in the following days. Then, on July 12, 2014 , the Company disclosed that the OCA results had also included lipid abnormalities in some patients. On this news, Intercept stock dropped nearly $200 per share. Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing. Keywords for this news article include: Harwood Feffer Llp, Clinical Trials and Studies. Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Clinical Trials Week


Story Tools